← ANALYST RATINGS · TIPRANKS
Xenon (XENE): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy1 Hold0 Sell
Ratings of 13 analysts in the last 3 months · top analysts only12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $69.00, the highest $82.00, the lowest $46.00. The average is +106.0% from the last price of $33.49.
Analyst ratings 23
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $34.00 → $35.00+2.9% | Hold | +4.5% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $34.00 → $35.00+2.9% | Hold | +4.5% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $33.00 → $34.00+3.0% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $35.00 → $34.00−2.9% | Hold | +1.5% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $35.00 → $34.00−2.9% | Hold | +1.5% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $34.00 → $33.00−2.9% | Hold | −1.5% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $41.00 → $35.00−14.6% | Hold | +4.5% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $40.00 → $35.00−12.5% | Hold | +4.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $40.00 → $35.00−12.5% | Hold | +4.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $39.00 → $34.00−12.8% | Hold | +1.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $41.00 → $35.00−14.6% | Hold | +4.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $42.00 → $36.00−14.3% | Hold | +7.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $77.00 | Buy | +129.9% | Reiterated | 12.10.26on TipRanks 08:10 | −1.7%next day −3.9% | ↗ |
| Name not given | — | $73.00 | Buy | +118.0% | Initiated | 05.10.26on TipRanks Oct 8 07:00 | −1.9%next day −3.2% · 5 days −5.1% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $70.00 | Buy | +109.0% | Reiterated | 01.10.26on TipRanks 07:08 | +4.5%next day −3.1% · 5 days −8.4% | ↗ |
| David Martin PhD★★★★★★★★★★#656 · hits 53% · avg +18.6% | Bloom Burton | $74.00 → $71.00−4.1% | Buy | +112.0% | Reiterated | 21.09.26on TipRanks Sep 22 08:50 | −3.5%next day +0.3% · 5 days −4.8% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $82.00 | Buy | +144.8% | Reiterated | 19.09.26on TipRanks Sep 21 02:00 | −3.5%next day +0.3% · 5 days −4.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $62.00 → $41.00−33.9% | Hold | +22.4% | Downgrade | 19.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $59.00 → $40.00−32.2% | Hold | +19.4% | Reiterated | 19.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $59.00 → $40.00−32.2% | Hold | +19.4% | Reiterated | 19.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $58.00 → $39.00−32.8% | Hold | +16.5% | Reiterated | 19.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $61.00 → $41.00−32.8% | Hold | +22.4% | Reiterated | 19.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $59.00 → $42.00−28.8% | Hold | +25.4% | Reiterated | 19.09.26on TipRanks 03:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | — | Buy | — | Reiterated | 18.09.26on TipRanks 10:45 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | — | Buy | — | Reiterated | 18.09.26on TipRanks 08:25 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $71.00 → $55.00−22.5% | Buy | +64.2% | Reiterated | 18.09.26on TipRanks 07:50 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 18.09.26on TipRanks 07:35 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $97.00 → $90.00−7.2% | Buy | +168.7% | Reiterated | 18.09.26on TipRanks 07:15 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $69.00 → $64.00−7.2% | Buy | +91.1% | Reiterated | 18.09.26on TipRanks 06:45 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $78.00 → $60.00−23.1% | Buy | +79.2% | Reiterated | 18.09.26on TipRanks 06:35 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $74.00 | Buy | +121.0% | Reiterated | 18.09.26on TipRanks 06:15 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $90.00 → $46.00−48.9% | Hold | +37.4% | Downgrade | 18.09.26on TipRanks 05:35 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 18.09.26on TipRanks 05:26 | −30.8%next day −3.5% · 5 days −8.3% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $75.00 | Buy | +123.9% | Reiterated | 17.09.26on TipRanks Sep 18 08:30 | −0.1%next day −30.8% · 5 days −34.5% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $81.00 → $70.00−13.6% | Buy | +109.0% | Assigned | 17.09.26on TipRanks Sep 18 06:50 | −0.1%next day −30.8% · 5 days −34.5% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $80.00 | Buy | +138.9% | Reiterated | 07.08.26on TipRanks 13:05 | −2.5%next day +1.4% · 5 days −2.0% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $90.00 | Buy | +168.7% | Reiterated | 06.08.26on TipRanks Aug 7 08:01 | +0.5%next day −2.5% · 5 days −1.7% | ↗ |
| Unknown Analyst | Leerink Partners | $50.00 → $63.00+26.0% | Buy | +88.1% | Reiterated | 22.06.26on TipRanks Jun 27 21:00 | +3.9%next day +1.1% · 5 days +10.2% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $65.00 → $100+53.8% | Buy | +198.6% | Assigned | 09.03.26on TipRanks 16:05 | −3.3%next day −2.5% · 5 days −8.0% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $55.00 | Buy | +64.2% | Reiterated | 26.02.26on TipRanks Feb 27 12:05 | +1.3%next day −3.3% · 5 days −5.2% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $60.00 | Buy | +79.2% | Initiated | 23.02.26on TipRanks 16:45 | +4.1%next day −1.3% · 5 days −1.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Xenon
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $71.42 at a price of $37.19 (+92.0%); now: $70.54 at $33.49 (+110.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 2 | 0 | 4 | 6 |
| Buy | 27 | 11 | 9 | 11 | 18 | 18 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.13 (from $-1.29 to $-0.94). Last quarter: $-1.11.
Best top-analyst consensus in the sector · Healthcare
About Xenon
- CEO: Ian C. Mortimer
- Employees: 364
- 3650 Gilmore Way, Burnaby, BC, V5G 4W8, CA
- www.xenon-pharma.com
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗